Welcome!

.NET Authors: Jayaram Krishnaswamy, Elizabeth White, Sematext Blog, ITinvolve Blog, Aditya Banerjee

News Feed Item

DSM reports solid Q3 results despite weak economic conditions

HEERLEN, NETHERLANDS -- (Marketwire) -- 11/06/12 --



* Q3 EBITDA from continuing operations EUR270 million (Q3 2011: EUR339 million)

* Life Sciences, driven by Nutrition, showed good performance, representing 76% of Q3 EBITDA

* Materials Sciences continued to perform well, except for caprolactam

* Further strategic progress with acquisitions

* Strong Q3 cash flow from operating activities of EUR253 million

* Outlook 2012 largely unchanged

Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing Board, said: "Despite a challenging global trading environment DSM continued to generate good results mainly driven by our Nutrition cluster. We continued to make good progress towards our strategic goals with the purchase of Tortuga and Cargill's cultures and enzymes business. We have now invested EUR2.3 billion in acquisitions since the end of 2010, of which EUR1.9 billion in Nutrition. With these acquisitions we are building new platforms and are strengthening our downstream network. This will create significant future value for the company whilst further increasing the resilience of DSM's earnings profile."

"Our Profit Improvement Program, designed in part to offset the impact of adverse external developments, is on track to deliver significant cost savings. We expect that trading conditions will remain tough. Our strong focus on cost control and cash flow together with our strong balance sheet leaves DSM well placed to navigate near term external challenges."

Find the tables on www.dsm.com or in the pdf version of the quarterly report.

Overview

During the third quarter of 2012, the weak conditions in the global economy seen throughout the previous quarter continued. The Eurozone challenges remained significant and the slow-down in China persisted. The US continued to grow at a modest rate. Despite these conditions, DSM continued to deliver solid operational results generating Q3 EBITDA of EUR270 million which included a negative caprolactam related impact of EUR105 million compared to Q3 2011.

Nutrition delivered a 15% higher EBITDA than in Q3 2011 as a result of organic growth, positive exchange rate effects and the contribution of Ocean Nutrition Canada.

Pharma results were adversely impacted by an uneven delivery pattern at DSM Pharmaceutical Products and by lower margins.

Performance Materials performed well, except for the continued weakness of caprolactam which impacted the results of DSM Engineering Plastics.

As expected, results at Polymer Intermediates declined significantly versus last year as already in Q2, mainly due to lower caprolactam margins.

Results at the Innovation Center improved as a result of higher Biomedical sales and the acquisition of Kensey Nash.

Cash provided by operating activities amounted to EUR547 million during the first three quarters of 2012 versus EUR479 million during the same period last year. Net debt increased by EUR839 million compared to year-end 2011 to a level of EUR1,157 million, mainly due to acquisitions.

Net sales

Organic sales development was -7% compared to Q3 2011 mainly due to Polymer Intermediates.

Nutrition continued to deliver organic growth by increasing volumes.

Pharma showed organic growth due to a more favorable product mix.

In Performance Materials the organic sales development of -7% was due to lower prices and lower volumes.

The organic sales development in Polymer Intermediates was due to lower volumes as well as lower caprolactam prices.

Business review by cluster

Nutrition

Organic sales growth was 1% compared to Q3 2011 with volume growth (2%) and slightly reduced prices (-1%). Sales growth was positively impacted by favorable exchange rates (4%) and the impact of the Ocean Nutrition Canada acquisition (4%).

Animal Nutrition & Health achieved modest volume growth despite the drought in the US which resulted in higher grain prices. This subsequently led to lower feed and meat production. Prices were slightly down.

Human Nutrition & Health prices were up slightly while volumes remained relatively stable. Nutritional Lipids experienced strong growth outside North America with synergies realized in line with targets. The integration of Ocean Nutrition Canada is on track with sales of EUR30 million and EBITDA of EUR8 million.

Personal care continued to grow especially in sun care and skin care.

DSM Food Specialties realized growth in all market segments. Especially enzymes showed strong organic growth.

EBITDA for the third quarter was EUR202 million, up EUR26 million from the same quarter a year earlier driven by higher margins, favorable exchange rates and the contribution of Ocean Nutrition Canada. At 21.4% the Q3 EBITDA margin was in line with the defined target of 20% - 23%.

Pharma

Net sales growth was 1% compared to Q3 2011 driven by a more favorable product mix (+1%), favorable exchange rates (+3%) and the deconsolidation of DSM Sinochem Pharmaceutical combined with the re-integration of the Maleic Anhydride and Derivatives business (-3%). Higher volumes at DSM Sinochem Pharmaceutical compensated for reduced volumes at DSM Pharmaceutical Products.

EBITDA for the quarter was EUR4 million, down from EUR13 million in the same quarter a year earlier. Lower volumes caused by uneven delivery patterns in the DSM Pharmaceutical Products business and lower margins at DSM Sinochem Pharmaceutical, despite higher volumes, had a negative impact.

Performance Materials

Organic sales development was -7% compared to Q3 2011 due to lower volumes in DSM Resins and lower volumes and lower prices at DSM Engineering Plastics, mainly as a result of lower polyamide-6 prices stemming from lower caprolactam prices. Currency developments and acquisitions had a positive impact on sales.

EBITDA was below Q3 last year as lower margins in the polyamide-6 value chain of DSM Engineering Plastics offset the good performance of the rest of the cluster. Despite ongoing subdued market conditions DSM Resins delivered improved results due to better margins and the implementation of cost saving actions.

Polymer Intermediates

Organic sales development was -24% compared to Q3 2011, due to 15% lower prices and 9% lower volumes. Currencies had a 5% positive impact on sales. Volumes were lower mainly due to scheduled caprolactam plant turnarounds in China and the US.

As expected, EBITDA was clearly below the record levels of Q3 2011. Caprolactam margins remained at the low levels reached at the end of Q2 2012. In addition, the scheduled plant turnarounds in China and the USA contributed to the lower EBITDA.

Innovation Center

Sales improved strongly compared to Q3 2011 as a result of higher Biomedical sales as well the acquisition of Kensey Nash which has been consolidated as of June 22.

EBITDA improved due to higher sales and the acquisition of Kensey Nash which now has been integrated into the biomedical business. Kensey Nash contributed in line with expectations with sales of EUR17 million and EBITDA of EUR7 million.

Corporate activities

The lower sales compared to Q3 2011 were due to the re-integration of the Maleic Anhydride and Derivatives business into the Pharma cluster.

EBITDA improved slightly compared to Q3 2011 as a result of the sale of certain assets at the Chemelot site which was partly offset by higher share based payment costs and higher project related costs.

Exceptional items

Exceptional items amounted to a loss of EUR26 million before tax (EUR22 million after tax). In connection with the Profit Improvement Program, restructuring costs and provisions were recognized for an amount of EUR13 million. Acquisition related costs amounted to EUR13 million.

Net profit

Net finance costs increased by EUR8 million compared to Q3 2011 to a level of EUR23 million mainly as a consequence of currency effects and less average cash at lower interest rates.

The effective tax rate was 18% compared to 19% for the full year 2011.

Net profit before exceptional items decreased by EUR56 million compared to Q3 2011 to EUR103 million mainly due to the lower Polymer Intermediates' operating profit.

Compared to Q3 2011 total net profit decreased by EUR90 million to EUR81 million.

Net earnings per ordinary share (continuing operations, before exceptional items) amounted to EUR0.61 in Q3 2012 compared to EUR0.94 in Q3 2011.

Cash flow, capital expenditure and financing

Cash provided by operating activities was EUR253 million in Q3 2012 compared to EUR323 million in Q3 2011. Year-to-date Q3 2012 cash provided by operating activities amounted to EUR547 million versus EUR479 million in the same period last year.

Excluding the acquisition effect of Ocean Nutrition Canada and Kensey Nash, Operating working capital decreased by EUR50 million compared to the level at the end of Q2 2012.

Cash flow related to capital expenditure amounted to EUR186 million in Q3 2012 compared to EUR144 million in Q3 2011. In the first three quarters of 2012 cash flow related to capital expenditure amounted to EUR474 million compared to EUR304 million in the same period last year.

Net debt increased by EUR839 million compared to year-end 2011 and stood at EUR1,157 million (gearing 16%).

DSM in motion: driving focused growth

DSM in motion: driving focused growth is the strategy that the company embarked on in September 2010. It marks the shift from an era of intensive portfolio transformation to a strategy of maximizing sustainable and profitable growth. DSM's strategic focus on Life Sciences (Nutrition and Pharma) and Materials Sciences (Performance Materials and Polymer Intermediates) is fueled by three main societal trends: Global Shifts, Climate & Energy and Health & Wellness. DSM aims to meet the unmet needs resulting from these societal trends with innovative and sustainable solutions.

Below is an update on DSM's strategic achievements in the third quarter.

Acquisitions & Partnerships: from portfolio transformation to driving focused growth

In July, DSM successfully completed the acquisition of Ocean Nutrition Canada, the leading global provider of fish-oil derived nutritional products to the dietary supplement and food and beverage markets. With this acquisition DSM strengthens and complements its Nutritional Lipids growth platform, established after the acquisition of Martek in 2011. DSM can now uniquely offer a full product range in the rapidly growing nutritional lipids category, offering both fish oil derived omega-3 fatty acids and microbially derived nutritional lipids.

In July, DSM successfully completed the acquisition of the Italian animal health and nutrition premix specialist, Cilpaz Srl. Although relatively minor in size, this acquisition underlines DSM's strategy of focused growth.

In August DSM entered into a definitive agreement to acquire Tortuga, a privately held Brazilian company, in a cash transaction for a total enterprise value of about EUR465 million (BRL 1,160 million). Tortuga is a leading company in nutritional supplements with a focus on pasture raised beef and dairy cattle. The company is headquartered in Sao Paulo, Brazil with approximately 1,200 employees. Subject to regulatory approvals, the transaction is expected to close in Q1 2013.

In October, DSM entered into a definitive agreement to acquire Cargill's cultures and enzymes business in a cash transaction for a total enterprise value of about EUR85 million. This business is a globally leading manufacturer of cultures and enzymes for the dairy and meat industries with manufacturing operations in Wisconsin (USA) and France. The business generates net sales of about EUR45 million per year with approximately 200 employees.

Since it set out its current strategic course in September 2010, DSM has invested EUR2.3 billion worth of growth-enhancing acquisitions. Nearly EUR1.9 billion is being spent in the Nutrition cluster as the company continues to further improve its attractive portfolio in health, nutrition and materials to deliver value with stronger, more stable growth and profitability.

Innovation: from building the machine to doubling innovation output

Bio-based Products & Services is making further strategic progress. The bio-succinic acid facility in Italy is currently in the start-up process. DSM and BP have extended their cooperation on the joint development of advanced bio-diesel. DSM successfully produced its first commercial batch of advanced C5 yeast for cellulosic ethanol producers.

High Growth Economies: from reaching out to being truly global

Sales to High growth Economies accounted for 37% of total sales versus 41% of total sales in Q3 2011 which was mainly due to lower caprolactam sales in China.

Net sales to China amounted to USD 398 million versus USD 554 million in Q3 2011 which was mainly due to lower sales prices at DSM Polymer Intermediates.

Outlook

The outlook for the global economy remains uncertain. DSM's Profit Improvement Program is fully on track and aims to deliver EUR150 million of benefits by 2014. This program together with an on-going focus on cash generation will help to offset adverse external factors. The acquisitions announced since the end of 2010 will create considerable economic value for DSM whilst increasing the resilience of its earnings.

Nutrition continues to demonstrate its resilience with EBITDA expected to be clearly above 2011. Ocean Nutrition Canada will add about EUR20 million in EBITDA in 2012.

Business conditions in Pharma are likely to remain challenging for the remainder of the year, although DSM continues to expect to deliver a slightly improved EBITDA despite the 50% deconsolidation of the anti-infectives business. DSM continues to seek opportunities to make further strategic progress in this cluster.

Full year EBITDA for Performance Materials is expected to be slightly below 2011, due to continuing weak market conditions for caprolactam.

The adverse market conditions for Polymer Intermediates are not expected to improve during Q4 and therefore DSM anticipates EBITDA to be clearly below the exceptional 2011 result.

For the Innovation Center, EBITDA is expected to improve compared to last year due to the acquisition of Kensey Nash which will add about EUR10 million in EBITDA in 2012.

Overall, DSM remains cautious about the economic outlook for the remainder of 2012. DSM's expectations for the year are largely in line with its previous guidance, with the exception of ongoing weakness in caprolactam which also affects the Performance Materials cluster.

Assuming no further deterioration of the economic conditions, and based on its strategy, financial strength and the Profit Improvement Program, DSM will move towards the 2013 EBITDA target.

Additional information

Today DSM will hold a conference call for the media from 07.30 AM to 08.00 AM CET which can be followed via a webcast and a conference call for investors and analysts from 09.00 AM to 10.00 AM CET. Details on how to access these calls can be found here. Also, information regarding DSM's third quarter results 2012 can be found in the Presentation to Investors, which can be downloaded from the Investors section of the DSM website.

Important dates
Annual Report 2012                            Wednesday, 20 February 2013
Report for the first quarter 2013             Thursday, 2 May 2013
Annual General Meeting of Shareholders        Friday, 3 May 2013
Report for the second quarter 2013            Tuesday, 6 August 2013
Report for the third quarter 2013             Tuesday, 5 November 2013

DSM - Bright Science. Brighter Living.™

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, pharmaceuticals, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM's 22,000 employees deliver annual net sales of about EUR9 billion. The company is listed on NYSE Euronext. More information can be found at www.dsm.com

Financial summary-pdf: http://hugin.info/130663/R/1655251/534840.pdf

Integrated report-pdf: http://hugin.info/130663/R/1655251/534841.pdf

Press release-pdf: http://hugin.info/130663/R/1655251/534839.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: DSM N.V. via Thomson Reuters ONE

[HUG#1655251]

For more information

Media
DSM, Corporate Communications
tel.: +31 (45) 5782421
e-mail: Email Contact

Investors
DSM, Investor Relations
tel.: +31 (45) 5782864
e-mail: Email Contact

www.dsm.com

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
We’re no longer looking to the future for the IoT wave. It’s no longer a distant dream but a reality that has arrived. It’s now time to make sure the industry is in alignment to meet the IoT growing pains – cooperate and collaborate as well as innovate. In his session at @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, will examine the key ingredients to IoT success and identify solutions to challenges the industry is facing. The deep industry expertise behind this presentation will provide attendees with a leading edge view of rapidly emerging IoT oppor...
In this Women in Technology Power Panel at 15th Cloud Expo, moderated by Anne Plese, Senior Consultant, Cloud Product Marketing at Verizon Enterprise, Esmeralda Swartz, CMO at MetraTech; Evelyn de Souza, Data Privacy and Compliance Strategy Leader at Cisco Systems; Seema Jethani, Director of Product Management at Basho Technologies; Victoria Livschitz, CEO of Qubell Inc.; Anne Hungate, Senior Director of Software Quality at DIRECTV, discussed what path they took to find their spot within the technology industry and how do they see opportunities for other women in their area of expertise.
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
DevOps Summit 2015 New York, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that it is now accepting Keynote Proposals. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete at launch. DevOps may be disruptive, but it is essential.
The Industrial Internet revolution is now underway, enabled by connected machines and billions of devices that communicate and collaborate. The massive amounts of Big Data requiring real-time analysis is flooding legacy IT systems and giving way to cloud environments that can handle the unpredictable workloads. Yet many barriers remain until we can fully realize the opportunities and benefits from the convergence of machines and devices with Big Data and the cloud, including interoperability, data security and privacy.
Wearable devices have come of age. The primary applications of wearables so far have been "the Quantified Self" or the tracking of one's fitness and health status. We propose the evolution of wearables into social and emotional communication devices. Our BE(tm) sensor uses light to visualize the skin conductance response. Our sensors are very inexpensive and can be massively distributed to audiences or groups of any size, in order to gauge reactions to performances, video, or any kind of presentation. In her session at @ThingsExpo, Jocelyn Scheirer, CEO & Founder of Bionolux, will discuss ho...
The 3rd International Internet of @ThingsExpo, co-located with the 16th International Cloud Expo - to be held June 9-11, 2015, at the Javits Center in New York City, NY - announces that its Call for Papers is now open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
Connected devices and the Internet of Things are getting significant momentum in 2014. In his session at Internet of @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, examined three key elements that together will drive mass adoption of the IoT before the end of 2015. The first element is the recent advent of robust open source protocols (like AllJoyn and WebRTC) that facilitate M2M communication. The second is broad availability of flexible, cost-effective storage designed to handle the massive surge in back-end data in a world where timely analytics is e...

ARMONK, N.Y., Nov. 20, 2014 /PRNewswire/ --  IBM (NYSE: IBM) today announced that it is bringing a greater level of control, security and flexibility to cloud-based application development and delivery with a single-tenant version of Bluemix, IBM's platform-as-a-service. The new platform enables developers to build ap...

Building low-cost wearable devices can enhance the quality of our lives. In his session at Internet of @ThingsExpo, Sai Yamanoor, Embedded Software Engineer at Altschool, provided an example of putting together a small keychain within a $50 budget that educates the user about the air quality in their surroundings. He also provided examples such as building a wearable device that provides transit or recreational information. He then reviewed the resources available to build wearable devices at home including open source hardware, the raw materials required and the options available to power s...
The Internet of Things promises to transform businesses (and lives), but navigating the business and technical path to success can be difficult to understand. In his session at @ThingsExpo, Sean Lorenz, Technical Product Manager for Xively at LogMeIn, demonstrated how to approach creating broadly successful connected customer solutions using real world business transformation studies including New England BioLabs and more.
Since 2008 and for the first time in history, more than half of humans live in urban areas, urging cities to become “smart.” Today, cities can leverage the wide availability of smartphones combined with new technologies such as Beacons or NFC to connect their urban furniture and environment to create citizen-first services that improve transportation, way-finding and information delivery. In her session at @ThingsExpo, Laetitia Gazel-Anthoine, CEO of Connecthings, will focus on successful use cases.
The Internet of Things is a misnomer. That implies that everything is on the Internet, and that simply should not be - especially for things that are blurring the line between medical devices that stimulate like a pacemaker and quantified self-sensors like a pedometer or pulse tracker. The mesh of things that we manage must be segmented into zones of trust for sensing data, transmitting data, receiving command and control administrative changes, and peer-to-peer mesh messaging. In his session at @ThingsExpo, Ryan Bagnulo, Solution Architect / Software Engineer at SOA Software, focused on desi...
Enthusiasm for the Internet of Things has reached an all-time high. In 2013 alone, venture capitalists spent more than $1 billion dollars investing in the IoT space. With "smart" appliances and devices, IoT covers wearable smart devices, cloud services to hardware companies. Nest, a Google company, detects temperatures inside homes and automatically adjusts it by tracking its user's habit. These technologies are quickly developing and with it come challenges such as bridging infrastructure gaps, abiding by privacy concerns and making the concept a reality. These challenges can't be addressed w...
The Domain Name Service (DNS) is one of the most important components in networking infrastructure, enabling users and services to access applications by translating URLs (names) into IP addresses (numbers). Because every icon and URL and all embedded content on a website requires a DNS lookup loading complex sites necessitates hundreds of DNS queries. In addition, as more internet-enabled ‘Things' get connected, people will rely on DNS to name and find their fridges, toasters and toilets. According to a recent IDG Research Services Survey this rate of traffic will only grow. What's driving t...
"For over 25 years we have been working with a lot of enterprise customers and we have seen how companies create applications. And now that we have moved to cloud computing, mobile, social and the Internet of Things, we see that the market needs a new way of creating applications," stated Jesse Shiah, CEO, President and Co-Founder of AgilePoint Inc., in this SYS-CON.tv interview at 15th Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example t...
The industrial software market has treated data with the mentality of “collect everything now, worry about how to use it later.” We now find ourselves buried in data, with the pervasive connectivity of the (Industrial) Internet of Things only piling on more numbers. There’s too much data and not enough information. In his session at @ThingsExpo, Bob Gates, Global Marketing Director, GE’s Intelligent Platforms business, to discuss how realizing the power of IoT, software developers are now focused on understanding how industrial data can create intelligence for industrial operations. Imagine ...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have s...